WuXi Biologics (Cayman)MEX:2269N 99 OCF Margin % is 38.31% as of Dec. 2025, which is 30% above its 10-year median of 29.58. GuruFocus rates MEX:2269N with a GF Score™ of 99/100 and a GF Value™ of MXN72.14. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, WuXi Biologics (Cayman) ranks better than 88.84% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:2269N vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s OCF Margin % distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (MEX:2269N) has a OCF Margin % of 38.31% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on WuXi Biologics (Cayman) and its competitors. This is 30% above median its historical median of 29.58. Over the past decade, WuXi Biologics (Cayman)'s OCF Margin % has ranged from 8.28 to 36.29. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #107 out of 959 companies in the Biotechnology industry, placing it in the top 11.2%.
Is WuXi Biologics (Cayman)'s OCF Margin % too high?
WuXi Biologics (Cayman)'s current OCF Margin % of 38.31% is 30% above median its 10-year median of 29.58. Over the past 10 years, this metric has ranged from a low of 8.28 to a high of 36.29. Based on the distribution chart, WuXi Biologics (Cayman) ranks #107 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #107 out of 959 companies for OCF Margin %. This places WuXi Biologics (Cayman) in the top 11% of its industry — outperforming the majority of peers. Historically, WuXi Biologics (Cayman)'s own OCF Margin % has ranged from 8.28 to 36.29 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current OCF Margin % is 38.31%, which is 30% above median its own 10-year median of 29.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
WuXi Biologics (Cayman) (MEX:2269N) has a current OCF Margin % of 38.31%. The stock's GF Value™ is MXN72.14, compared to a current price of MXN62.53 — trading 13.3% below its estimated fair value. The current OCF Margin % is 38.31%, which is 30% above median its 10-year median of 29.58. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For WuXi Biologics (Cayman) (MEX:2269N), the current OCF Margin % is 38.31% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (MEX:2269N) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of MXN62.53 is trading 13.3% below its estimated GF Value™ of MXN72.14.
Key valuation signals for MEX:2269N:
OCF Margin %: 38.31% (30% above median its 10-year median of 29.58)
GF Value™: MXN72.14 vs. price of MXN62.53 (13.3% below fair value)
No single metric tells the full story. See the MEX:2269N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score
Get the complete analysis for MEX:2269N
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:2269N has been successfully added to your 
